A phase 1 placebo-controlled dose-escalation safety and pharmacokinetic study of in-007, a nebulized, pan-sars ACE2-decoy therapeutic for pandemic preparedness
Active Definitive Contract Awarded
- Contract number
- HT942525CE039
- Awardee
-
Inhalon Biopharma, Inc. UEI HFQSJ2GMNRU6
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $3,175,643
Award facts
- Opportunity
-
- HT942524SJWMR Solicitation number
- Contract value 100% obligated
- $3,175,643.00 Current and potential, with all options
- Completion date 49% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 44 offers Basic Research
- Pricing
- Fixed Price Level of Effort
- Place of performance
- Morrisville, NC, USA
- Research
- SBIR Program Phase III Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $3.18M fixed-price level of effort contract to Inhalon Biopharma, Inc., a clinical-stage biopharmaceutical company based in Morrisville, North Carolina, for a Phase I placebo-controlled dose-escalation safety and pharmacokinetic study of IN-007, a nebulized pan-SARS ACE2-decoy therapeutic. This Small Business Innovation Research (SBIR) Program Phase III action supports pandemic preparedness initiatives by advancing an innovative inhaled treatment platform that leverages human ACE2 receptor decoys to neutralize respiratory pathogens. The contract, awarded on September 22, 2025, carries no set-aside designation and is scheduled for completion by December 31, 2027, with all work to be performed at the contractor's Morrisville facilities.
IN-007 represents Inhalon's specialized approach to respiratory disease therapeutics through direct pulmonary administration via handheld nebulizers, enabling broad-spectrum protection against pandemic pathogens. The study will evaluate the safety profile and pharmacokinetic properties of the nebulized therapeutic in human subjects, supporting regulatory pathway advancement toward clinical deployment. This contract builds upon Inhalon's existing federal partnerships, including previous Defense Health Agency contracts and multiple National Institute of Allergy and Infectious Diseases grants totaling approximately $3M, collectively positioning the company as a key contributor to the federal government's pandemic preparedness and respiratory infection treatment capabilities.
Quick answers
Who was awarded contract HT942525CE039?
HT942525CE039 was awarded to Inhalon Biopharma, Inc. by Defense Health Agency (Department of Defense) on September 22, 2025.
How much is contract HT942525CE039 worth?
The government has obligated $3,175,643 on HT942525CE039.
Was contract HT942525CE039 competed?
The extent of competition for HT942525CE039 was full and open competition. The government received 44 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award